← 프로그램 목록
Phase 2Active

NK immunotherapy

Beijing Biotech

비교

NK immunotherapy(Beijing Biotech)은 Recurrent Pharyngeal Cancer 표적 치료제로, Recurrent Ovarian Cancer 영역에서 개발·상용화 중입니다. 작용기전: target/off-tumour toxicity, resistance to dominant suppressive pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapsed or refra. 차별점: novel anti-human epidermal growth factor receptor 2 (HER2) CAR-NK cell using an affibody molecule as the extracellular target.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 9일 (5일 전)PK/독성 2026년 7월 9일 (5일 전)

Recurrent Pharyngeal Cancer

Recurrent Ovarian Cancer

Active

Technology

구조모아 · StructureMoa에서 구조 검색

NK cell using an affibody molecule as the extracellular targeting d

Lentiviral transduction of NK-92 cells with the MSLN-CAR, followed by sorting and cloning,

humanized ACE2-NSG mice

novel anti-human epidermal growth factor receptor 2 (HER2) CAR-NK cell using an affibody molecule as the extracellular target

Mechanism of Action

target/off-tumour toxicity, resistance to dominant suppressive pathway

NK cells exhibited effective cytotoxicity

apoptosis and necrotic lesions in tumor tissues, promoted NK cell infiltration into the tumor site, and regulated the release of

HER2-positive

downregulation of activating ligands, and upregulation of immune checkpoints

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 58건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 4 · Phase 1, Phase 2 · Phase 2
  • Status: Unknown status · Recruiting · Completed
  • 주요 endpoint: The primary study endpoint was the proportion of subjects who had converted their sputum cultures to negative at the end of treatment. · Incidence of Dose-limiting toxicities (DLTs) [Safety and Tolerability] · Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] · For all participants with Interstitial Lung Disease (ILD) · For all participants with Systemic Sclerosis (SSc)
  • 등록된 결과: ORR 0%
  • 핵심: This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients wi…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

NK immunotherapy은 어떤 치료제인가요?
NK immunotherapy(Beijing Biotech)은 Recurrent Pharyngeal Cancer 표적 항체로, Recurrent Ovarian Cancer 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
NK immunotherapy의 임상 단계는?
NK immunotherapy의 현재 단계는 Phase 2입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.